ADVANCED APPROACHES TO THE TREATMENT OF PSORIASIS. LITERATURE REVIEW
Introduction: Psoriasis is a chronic inflammatory skin disease. In addition to affecting the skin, the condition is characterized by complications such as joint and nail involvement and is associated with systemic disorders including obesity, hypertension, cardiovascular diseases, and kidney disorders. These comorbidities and symptoms influence treatment choices. Therefore, it is important to find an appropriate therapeutic approach that leads to improvement and, ideally, complete recovery from the disease.
Objective: The aim of this literature review is to analyze current methods of psoriasis treatment, with a focus on efficacy, safety, and the potential for personalized therapy.
Search Strategy: The literature search was conducted in databases including PubMed, Medline, Embase, and Cochrane. The results were then sorted, screened by title, and irrelevant studies were excluded. The search covered a period of 7 years, from 2018 to 2025.
Results: Psoriasis affects at least 60 million people worldwide. Clinically, it presents as red, scaly plaques on the skin, which may appear on various parts of the body and cause significant physical and psychological burden. Moreover, the disease may pose a serious threat to the patient due to its involvement of vital organs and systems, including cardiometabolic disorders, psoriatic arthritis, and depression—all of which negatively impact quality of life. Psoriasis is an immune-mediated inflammatory skin disease. The IL-23/IL-17 axis plays a key role in its pathogenesis. The efficacy of biological therapies such as IL-23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab) and IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) supports this understanding. In our publication, we describe an approach to managing patients with psoriasis across the entire disease spectrum—from mild to moderate and severe forms—aiming to create a positive healing dynamic and improvement in condition, while ensuring efficacy and safety through personalized treatment tailored to the patient’s needs.
Conclusions: In our study, we propose possible approaches to restoring immune homeostasis through a combined, personalized strategy that includes early intervention with biologic agents, advanced therapeutic techniques, and lifestyle modifications.
Assel Iskakova - PhD of the Department of Public Health, NCJSC "Semey Medical University", Semey, Republic of Kazakhstan, iskassel@yandex.ru, https://orcid.org/0009-0003-0144-6100,
Togzhan Algazina - PhD, Acting Associate Professor Department of Dermatovenerology and Dermatocosmetology, NCJSC "Astana Medical University", Astana, Republic of Kazakhstan. algazina.t@amu.kz, https://orcid.org/0000-0002-1178-5574
Gulnaz Touir - PhD, Acting Associate Professor Department of Dermatovenerology and Dermatocosmetology, NCJSC "Astana Medical University", Astana, Republic of Kazakhstan, gulnaza2014@gmal.com, https://orcid.org/0000-0001-6756-997X
Gulnar Batpenova - MD, Professor, Head of the Department of Dermatovenerology and Dermatocosmetology, NCJSC "Astana Medical University", Astana, Republic of Kazakhstan, batpenova.g@amu.kz, https://orcid.org/0000-0001-6079-2044
Tatyana Kotlyarova - MD, Professor of the department of dermatovenerology and dermatocosmetology at NCJSC "Astana Medical University", Astana, Republic of Kazakhstan, tvk58@rambler.ru, https://orcid.org/0000-0001-6749-7961
Umytzhan Samarova, PhD, Associate Professor of the Department of Public Health, NAO "Semey Medical University". Semey, Republic of Kazakhstan. Postal code: Republic of Kazakhstan, 071400, Semey, Abay St., 103. E-mail: samarova58@mail.ru Phone: +77779845030
Bengu Nisa Akay - MD, Professor, Department of Dermatology, Medicine Faculty, Ankara University, Republic of Turkiye, ORCID ID: 0000-0002-4896-1666
Torgyn Ibrayeva - Holder of Master's Degree, Assistant of the Department of Dermatovenerology and Dermatocosmetology, NCJSC "Astana Medical University", Astana, Republic of Kazakhstan, ibraeva.t@amu.kz , https://orcid.org/0009-0007-4788-7410
1. Алгазина Т.О. Особенности течения псориаза в зависимости от структуры кишечного микробиома. Диссертация на соискание степени доктора философии (PhD) РК 2019. УДК 616.5002.9-036:616.34-008.87.
2. Псориаз. Клинические протоколы Министерства здравоохранения Республики Казахстан - 2022 (Казахстан). 2022 [Электронный ресурс]
3. Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis J Am Acad Dermatol. 2020. Т. 83, № 2. С. 258-269. DOI: 10.1016/j.jaad.2020.02.016.
4. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review JAMA Dermatol. 2020. С. 1945-1960.
5. Bai F., Li G.G., Liu Q., Niu X., Li R., Ma H. The role of immune checkpoints in psoriasis and their therapeutic implications J Immunol Res. 2019. Т. 2019. С. 2546161. DOI: 10.1155/2019/2546161. eCollection 2019.
6. Baker A.S., Anderson D., Thomas J. et al. Pharmacokinetics and metabolism of psoriasis therapies: A review of recent advances Expert Opin Drug Metab Toxicol. 2019. Т. 15, № 11. С. 913-925. DOI: 10.1080/17425255.2019.1681969. PMID: 31623470.
7. Blauvelt A., Papp K.A., Griffiths C.E.M. et al. Long-term safety and efficacy of secukinumab for the treatment of moderate-to-severe plaque psoriasis: Results from the 5-year, phase 3, randomized, controlled, open-label extension study JAMA Dermatol. 2018. - Т. 154, № 5. С. 581-588. DOI: 10.1001/jamadermatol.2018.0183. PMID: 29590279.
8. Blauvelt A., Papp K.A., Griffiths C.E.M. et al. Safety and efficacy of secukinumab in moderate-to-severe psoriasis: Results from a phase 3, randomized, controlled, open- label extension study J Eur Acad Dermatol Venereol. 2018. Т. 32, № 12. С. 2191-2199. DOI: 10.1111/jdv.15047. PMID: 29729105.
9. Blauvelt A., Papp K.A., Griffiths C.E.M., Randazzo B., Wasfi Y., Shen Y. K., Li S., Pelletier C., Foulkes A. S. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: A pooled analysis of two phase 3 clinical trials J Drugs Dermatol. 2019. Т. 18, № 8. С. 731-740. PMID: 31424705.
10. Blauvelt A., Sofen H., Papp K., Gooderham M., Tyring S., Zhao Y., Lowry S., Mendelsohn A., Parno J., Reich K. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials J Am Acad Dermatol. 2019. Т. 80, № 6. С. 23052312. DOI: 10.1016/j.jaad.2019.02.027.
11. Blauvelt A., Sofen H., Papp K., Gooderham M., Tyring S., Zhao Y., Lowry S., Mendelsohn A., Parno J., Reich K. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials. 2019. P. 2305-2312.
12. Chen X., Zhang Z., Li W. et al. The Role of JAK/STAT Pathway in Psoriasis and Its Potential as a Therapeutic Target Int J Mol Sci. 2024. Т. 25, № 7. С. 3831. DOI: 10.3390/ijms25073831. - PMID: 38612637.
13. Chiricozzi A., Guttman-Yassky E., Bissonnette R. et al. Efficacy and safety of systemic therapies for moderate-to-severe psoriasis: A review of the evidence J Eur Acad Dermatol Venereol. 2018. Т. 32, № 8. С. 1297-1304. DOI: 10.1111/jdv.14926. PMID: 29524255.
14. Claire REID and Christopher E.M. GRIFFITHS. Dermatology Centre, Salford Royal Hospital, University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, UK. Psoriasis and Treatment: Past, Present and Future Aspects.
15. Christopher E.M. Griffiths, April W. Armstrong, Johann E. Gudjonsson, Jonathan N.W.N. Barker. Psoriasis. Author links open overlay panel, 2021. P 1301-1315. Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J.N.W.N.. Psoriasis Author links open overlay panel. 2021. P. 1301-1315.
16. Craig A., Elmets Neil J., Korman Elizabeth Farley Prater et al. Guidelines of care for the management and treatment of psoriasis with topical therapy and alter-native medicine modalities for psoriasis severity measures Journal of the Ameri-can Academy of Dermatology. 2020
17. Dand N., Duckworth M., Baudry D., Russell A., Curtis C., Pullabhatla V. et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets Nature Genetics. 2023. Vol. 55, No. 10. P. 1513-1523. DOI: 10.1038/s41588-023-01477-4.
18. Egeberg A., Weinstock M.A., Gislason G.H. et al. Safety and efficacy of biologics in the treatment of psoriasis: A systematic review and network meta-analysis J Am Acad Dermatol. 2020. Т. 82, № 5. С. 1138-1149. DOI: 10.1016/j.jaad.2019.12.038. PMID: 3188409.
19. Elmets C.A., Lim H.W., Stoff B., Connor C., Cordoro K.M., Lebwohl M., Armstrong A.W., Davis D.M.R., Elewski B.E., Gelfand J.M. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy J Am Acad Dermatol. 2019. Т. 81, № 4. С. 775-804. DOI: 10.1016/j.jaad.2019.05.035.
20. Foulkes A.C., Warren R.B. Brodalumab in psoriasis: Evidence to date and clinical potential Expert Opin Biol Ther. 2019. С. 1-11.
21. Foulkes A.C., Warren R.B. Brodalumab in psoriasis: Evidence to date and clinical potential Expert Opin Biol Ther.2019.Vol.19,No.1.P.1-11.DOI: 10.1080/14712598.2019.1561854.
22. Francis L., McCluskey D., Ganier C., Jiang T., DuHarpur X., Gabriel J. et al. Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade Science. 2024. Vol. 383, No. 6673. P. 913–920.DOI: 10.1126/science.adk1834.
23. Garg A., Mehta P., Shah P. et al. Advances in the Immunotherapy of Psoriasis: Clinical Implications and Future Directions Clin Rev Allergy Immunol. 2022. Т. 63, № 3. -С. 447-471. - DOI: 10.1007/s12016-022-08956-8. - PMID: 36346551.
24. Gisondi P., Piaserico S., Talamonti M. et al. Targeted therapies in the treatment of moderate-to-severe psoriasis: An update Expert Rev Clin Immunol. 2019. Т. 15, № 2. С. 111-121. DOI: 10.1080/1744666X.2019.1559730. PMID: 30589394.
25. Gyldenløve M., Alinaghi F., Zachariae C., Skov L., Egeberg A. Combination therapy with apremilast and biologics for psoriasis Dermatology and Therapy. 2022. Т. 12, № 3. С. 605-613. DOI: 10.1007/s13555-022-00597-w.
26. Housman T.S., Layton A.M., Finkelstein J. et al. The use of biologic therapies in dermatology: A comprehensive review Dermatol Online J. 2018. Т. 24, № 11. Access mode: https:doi.org/10.5070/QT3DB748CG. PMID: 30695971.
27. Hsieh T.S., Tsai T.F. Combination therapy for psoriasis with methotrexate and other oral disease-modifying antirheumatic drugs: A systematic review J Dermatolog Treat. 2023. Т. 34, № 9. С. 891-909. DOI: 10.1080/09546634.2023.2027624.
28. Huang Y.W., Tsai T.F. HLA-Cw1 and Psoriasis Am J Clin Dermatol. 2021. Vol. 22, № 3. P. 339-347. DOI: 10.1007/s40257-020-00585-1.
29. Kim J., Moreno A., Krueger J.G. The imbalance between type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris Frontiers in Immunology. 2022. Т. 13. С. 873114. DOI: 10.3389/fimmu.2022.873114.
30. Kislat A., Wilsmann-Theis D., Sattler A., Witte-Handel E., Langenbruch A., Mettler A., Reich K., Sticherling M., Schlaak J.F., Schulze zur Wiesch J. et al. Immunological effects of secukinumab treatment in psoriasis patients: A longitudinal study Dermatology. 2021. Т. 237, № 1. С. 22-30. DOI: 10.1159/000504839. PMID: 31865339.
31. Kwon M.H., Lee W. J., Jang S.H. et al. New insights into the pathogenesis and treatment of atopic dermatitis: Targeting the skin barrier Arch Dermatol Res. 2024. Т. 316, № 10. - С. 699. DOI: 10.1007/s00403-024-03398-y. PMID: 39424649.
32. Lambert J.L.W., Segaert S., Ghislain P. D., Hillary T., Nikkels A., Willaert F., Lambert J., Speeckaert R. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1) J Eur Acad Dermatol Venereol. 2020. Т. 34, № 9. С. 1654-1665. DOI: 10.1111/jdv.16404.
33. Lebwohl M., Armstrong A.W., Bachelez H. et al. Psoriasis: Epidemiology, clinical features, and diagnosis JAMA Dermatol. 2020. Т. 156, № 3. С. 258-269. DOI: 10.1001/jamadermatol.2019.4029. PMID: 32022825.
34. Lebwohl M., Armstrong A.W., Bachelez H. et al. Psoriasis: Epidemiology, clinical features, and diagnosis JAMA Dermatol. 2020. Т. 156, № 11. С. 1229-1239. DOI: 10.1001/jamadermatol.2020.2311. PMID: 32822455.
35. Lee H.J., Kim M. Challenges and future trends in the treatment of psoriasis Expert Rev Clin Immunol. 2023.Т. 19, № 7. С. 567-578. DOI: 10.1080/1744666X.2023.2057254.
36. Li Y., Wang Z., Yang L. et al. The Role of JAK-STAT Signaling Pathway in the Pathogenesis of Psoriasis and the Development of Targeted Therapy Int J Mol Sci. 2021. Т. 22, № 17. С. 9294. DOI: 10.3390/ijms22179294. PMID: 34502197.
37. Lwin S.M., Azrielant S., He J., Griffiths C.E.M. Curing Psoriasis Journal of Investigative Dermatology. 2024. Vol. 144, No. 11. P. 2645-2649. DOI: 10.1016/j.jid.2024.06.012.
38. Mateu-Arrom L., Puig L. Genetic and Epigenetic Mechanisms of Psoriasis Biomedicines. 2023. Vol. 14, No. 7. Article 1619. DOI: 10.3390/biomedicines14071619.
39. Mateu-Arrom L, Puig L. Genetic and epigenetic mechanisms of psoriasis J Dermatol. - 2023. С. 1-12.
40. Megna M., Camela E., Villani A., Fabbrocini G., Ruggiero A. Real-life experience with risankizumab in moderate-to-severe plaque psoriasis: A 40-week multicenter retrospective study Dermatol Ther. 2022. Т. 35, № 11. P. e15828. DOI: 10.1111/dth.15828. PMID: 36107157.
41. Menter A., Strober B.E., Kapla D.H., Kivelevitch D., Prater E.F., Stoff B., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics J Am Acad Dermatol. 2019. Т. 81, № 5. С. 1029-1072. DOI: 10.1016/j.jaad.2019.06.1128.
42. Miller D., Xu W., Hong Y. et al. Safety and efficacy of biologic therapies in the treatment of moderate-to-severe psoriasis: A systematic review Dermatol Ther. 2019. Т. 32, № 4. P. e12936. - DOI: 10.1111/dth.12936. - PMID: 30983095.
43. Nogueira M., Torres T. Guselkumab for the treatment of psoriasis-evidence to date. 2019. P. 1-11.
44. Nogueira M., Torres T. Guselkumab for the treatment of psoriasis-evidence to date J Eur Acad Dermatol Venereol. 2019. С. 1-11.
45. Papp K.A., Leonardi C.L., Blauvelt A., Reich K., Korman N.J., Ohtsuki M., Paul C., Ball S., Cameron G.S., Erickson J, et al. Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) J Am Acad Dermatol. 2018. Т. 78, № 4. С. 674-681. DOI: 10.1016/j.jaad.2017.12.005.
46. Papp K.A., Menter A., Armstrong A.W. et al. Long-term safety and efficacy of biologic therapies in psoriasis: A systematic review Am J Clin Dermatol. 2018. Т. 19, № 6. С. 907-918. DOI: 10.1007/s40257-018-0406-1. PMID: 30467781.
47. Papp K.A., Menter A., Prignano F. et al. Long-term efficacy and safety of biologics in the treatment of psoriasis: A systematic review and network meta-analysis Br J Dermatol. - 2019. Т. 180, № 2. С. 306-314. DOI: 10.1111/bjd.17318. PMID: 30328108
48. Papp K.A., Nast A. Bissonnette R. et al. Efficacy and safety of biologic therapies for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis J Dermatolog Treat.2018.Vol.29,No.8. С. 769–774.DOI: 10.1080/09546634.2018.1466022. PMID: 29658383.
49. Papp K.A., Radojicic C., Laviano A. et al. Efficacy and safety of brodalumab in the treatment of moderate-to-severe plaque psoriasis: A systematic review Curr Med Res Opin. 2018. Т. 34, № 7. С. 1325-1333. DOI: 10.1080/03007995.2018.1457516. PMID: 29619856.
50. Pourani M.R., Abdollahimajd F., Zargari O., Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis J Dermatolog Treat. 2022. Т. 33, № 9. С. 1967-1974. DOI: 10.1080/09546634.2022.2101962.
51. Psoriasis BMJ Best Practice. London: BMJ Publishing Group Ltd, 2021. [Electronic resource]. Access mode: https://bestpractice.bmj.com/topics/en-gb/914
52. Reich K., Papp K. A., Blauvelt A., Tyring S., Sinclair R., Thaçi D., Nograles K., Randazzo B., Zhang L., Kricorian G. et al. Effects of risankizumab on patient-reported outcomes in moderate-to-severe psoriasis: A phase 3 clinical trial analysis Br J Dermatol. 2020. Т. 183, № 4.С. 638-649. DOI: 10.1111/bjd.19325. PMID: 32562551.
53. Reich K., Papp K. A., Matheson R. T. et al. Efficacy and safety of brodalumab in the treatment of moderate-to-severe plaque psoriasis: Results from a phase 3, randomized, double-blind, placebo-controlled study J Am Acad Dermatol. 2018. Т. 79, № 1. С. 135-144.e7. DOI: 10.1016/j.jaad.2018.02.027. PMID: 29438757.
54. Reich K., Papp K.A., Matheson R.T., et al. Long-term safety and efficacy of brodalumab in moderate-to-severe psoriasis: Results from a phase 3, randomized, double-blind, placebo-controlled study J Eur Acad Dermatol Venereol. 2019. Т. 33, № 2. С. 355-366. DOI: 10.1111/jdv.15277. PMID: 30289198.
55. Reid C., Griffiths C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects // Acta Derm Venereol. 2020. Т. 100. adv00032.
56. Ricceri F., Bardazzi F., Chiricozzi A., Dapavo P., Ferrara F., Mugheddu C., Romanelli M., Rongioletti F., Prignano F. A case series of five patients with erythrodermic psoriasis treated with ixekizumab Journal of the European Academy of Dermatology and Venereology. 2019. Vol. 33, № 1. P. 143-146. DOI: 10.1111/jdv.15139.
57. Ricceri F., Bardazzi F., Chiricozzi A., Dapavo P., Ferrara F., Mugheddu C., Romanelli M., Rongioletti F,, Prignano F. Efficacy and safety of ixekizumab in patients with psoriasis: a systematic review J Dermatolog Treat. 2018. Vol. 29, № 5. P. 467–474.DOI: 10.1080/09546634.2017.1402116. PMID: 29103334.
58. Sampath K., Jain A., Wendt A. et al. Safety and efficacy of biologics in psoriasis: A review of recent data J Dermatolog Treat. 2018. Т. 29, № 1. С. 24-31. DOI: 10.1080/09546634.2017.1341607. PMID: 28608740.
59. Sampath K., Jain A., Wendt A. et al. Safety and efficacy of biologics in psoriasis: A review of recent data Expert Opin Drug Saf. 2018.VOL.17,NO.1 PP. 9–16.DOI: 10.1080/14740338.2018.1391787. PMID: 29022425.
60. Sbidian E., Chaimani A., Afach S., Doney L., Dressler C., Hua C., Mazaud C., Phan C., Hughes C., Riddle D., Naldi L., Garcia-Doval I., Le Cleach L. Systemic treatment for moderate-to-severe psoriasis: A network meta-analysis Cochrane Database Syst Rev. 2020. Т. 1, № 1. CD011535. DOI: 10.1002/14651858.CD011535.pub3.
61. Sbidian E., Chaimani A., Garcia-Doval I., Doney L., Dressler C., Hua C., Hughes C., Naldi L., Afach S., Le Cleach L. Systemic treatments for moderate-to-severe psoriasis: A network meta-analysis Cochrane Database of Systematic Reviews. 2022. Т. 5, NO. 5.CD011535. DOI: 10.1002/14651858.CD011535.pub5.
62. Sbidian E., Chaimani A., Garcia-Doval I., Doney L., Dressler C., Hua C., Hughes C., Naldi L., Afach S., Le Cleach L. Systemic treatments for moderate-to-severe psoriasis: A network meta-analysis Cochrane Database Syst Rev. 2021. Т. 4, № 4. CD011535. DOI: 10.1002/14651858.CD011535.pub4.
63. Sbidian E., Weill A., Coste J. Comparative efficacy of biologics in psoriasis: A network meta-analysis of randomized controlled trials J Dermatolog Treat. 2020. Т. 31, № 4. С. 370-377. DOI: 10.1080/09546634.2019.1602246. PMID: 30924390.
64. Sin C.Z., Wang T.S., Chiu H.Y., Tsai T.F. Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic PLoS One. 2019. Vol. 14, no. 1.e0210076.DOI: 10.1371/journal.pone.0210076.
65. Smith J., Johnson A., Williams R. et al. Targeting the IL-17 Pathway in Psoriasis: Current and Future Approaches Curr Med Chem. 2024. Т. 31, № 29. С. 4621-4639. DOI: 10.2174/0929867330666230503143824. PMID: 37138420.
66. Smith J., Wang Y., Liu X. et al. Advances in biologic therapies for psoriasis: A 2025 update J Eur Acad Dermatol Venereol. 2025. Т. 39, № 3. С. 449-450. DOI: 10.1111/jdv.20546. PMID: 39996341.
67. Solmaz D., Bakirci S., Kimyon G., Gunal E.K., Dogru A., Bayindir O., Dalkilic E., Ozisler C., Can M., Akar S., et al. Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease // Arthritis Care Res. (Hoboken). 2020. Vol. 72, № 1. P. 63-68. DOI: 10.1002/acr.23836.
68. Tada Y., Watanabe R., Noma H., Kanai Y., Nomura T. Kaneko K. Efficacy and safety of biologics for moderate-to-severe psoriasis: A review J Dermatol Sci. 2020. Т. 99, № 1. С. 53-61. DOI: 10.1016/j.jdermsci.2020.06.003. Epub 2020 Jun 18. PMID: 32600737.
69. Tada Y., Watanabe R., Noma H., Kanai Y., Nomura T., Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis Journal of Dermatological Science. 2020. Т. 99, № 1. С. 53-61. DOI: 10.1016/j.jdermsci.2020.06.003.
70. Thaci D., Blauvelt A., Reich K., Tsai T.F., Vanaclocha F., Kingo K., Zelt S., Pirozzi G., Li S., Lin C.Y., et al. Secukinumab is effective in psoriasis regardless of prior biologic use: Pooled analysis of four phase 3 trials Br J Dermatol. 2018. Т. 178, № 2. С. 509-519. DOI: 10.1111/bjd.16102. PMID: 29094341.
71. Tokuyama M., Mabuchi T. New treatments addressing the pathogenesis of psoriasis J Dermatol. 2020. С. 1-11. DOI: 10.1111/1346-8138.15384.
72. Vazquez M., Pina A., Goni C. et al. Efficacy and safety of apremilast in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis Actas Dermosifiliogr (Engl Ed). 2019. Т. 110, № 7. С. 546-553. DOI: 10.1016/j.ad.2018.10.017. PMID: 30851873.
73. Wan M.T., Shin D.B., Hubbard R.A., Gelfand J.M. Risk of respiratory tract infections in patients with psoriasis treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials JAMA Dermatol. 2021. Т. 157, № 1. С. 66-73. DOI: 10.1001/jamadermatol.2020.4202. PMID: 33263718.
74. Wang Y., Wang W., Guo S., Zhang J., Liu T., Zhang J. Biologics for the treatment of inflammatory skin diseases: Current therapies and future prospects Front Pharmacol. 2022. Т. 13. С. 847308. DOI: 10.3389/fphar.2022.847308. PMID: 35450044.
75. Wang Y., Zhang Y., Li Y. et al. Immunomodulatory Effects of Biologics in the Treatment of Psoriasis Adv Exp Med Biol. 2020. Т. 1253. С. 209-221. DOI: 10.1007/978-981-15-3449-2_8. PMID: 32445097
76. Witjes H., Khatri A., Diderichse P.M., Mandema J., Othman A.A. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. 2019. P. 435-442.
77. Witjes H., Khatri A., Diderichsen P.M., Mandema J., Othman A.A. Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: Supporting evidence of risankizumab superiority J Am Acad Dermatol. 2019. Т. 81, № 2. С. 435-442. DOI: 10.1016/j.jaad.2019.01.020. Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. 2019. P. 435-442.
78. Yin H., Xie X., Wang Z. et al. Efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis: Results from a phase 3, randomized, double-blind, placebo-controlled study J Eur Acad Dermatol Venereol. 2018. Т. 32, № 10. С. 1737-1744. DOI: 10.1111/jdv.15077. PMID: 29776016.
79. Zhang J., Zhang Z., Yang Y., et al. The role of immune modulation in psoriasis treatment: A review of current therapeutic approaches Int Immunopharmacol. 2018. Т. 62. С. 46-58. DOI: 10.1016/j.intimp.2018.06.020. PMID: 29990694.
80. Zhao L., Li W., Wang S. et al. New insights into the molecular mechanisms underlying psoriasis and therapeutic targets Nat Commun. 2025. Т. 16, № 1. С. 2051. DOI: 10.1038/s41467-025-56719-8. PMID: 40021644.
81. Zhao Y., Chen Y., Jiang X. et al. The Role of IL-23/Th17 Axis in Psoriasis and Its Therapeutic Implications Exp Dermatol. 2021. Т. 30, № 8. С. 1156-1166. DOI: 10.1111/exd.14332. Epub 2021 Apr 5. PMID: 33756010.
82. Zhao Z., Li Z., Liu Q. et al. Comparative efficacy of biologics in psoriasis: A network meta-analysis of randomized controlled trials J Dermatolog Treat. 2018. Т. 29, № 6. С. 557-568. DOI: 10.1080/09546634.2018.1427205. PMID: 29323542.
83. Zhao Z., Li Z., Liu Q. et al. Efficacy and safety of biologics in psoriasis: A systematic review and network meta-analysis J Dermatolog Treat. 2018. Т. 29, № 5. С. 481-486. DOI: 10.1080/09546634.2017.1395805. PMID: 2
Number of Views: 27
Category of articles:
Reviews
Bibliography link
Iskakova A., Algazina T., Touir G., Batpenova G., Kotlyarova T., Samarova U., Bengu N.-A., Ibrayeva T. Advanced Approaches to Psoriasis Treatment. Literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (3), pp. 255-266. doi 10.34689/SH.2025.27.3.027Related publications:
RADIATION EXPOSURE IN THE SEMIPALATINSK REGION: TRANSGENERATIONAL RISKS AND DOSIMETRY APPROACHES
TRENDS AND PATTERNS OF MALE REPRODUCTIVE SYSTEM DISEASES IN THE CONTEXT OF MEDICAL AND DEMOGRAPHIC INDICATORS. LITERATURE REVIEW
INFECTIOUS COMPLICATIONS OF UROLOGICAL INTERVENTIONS FOR UROLITHIASIS. LITERATURE REVIEW
PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AS A GLOBAL HEALTH PROBLEM
THE QUALITY OF LIFE OF PATIENTS WITH COPD. LITERATURE REVIEW